Welcome to Carelukast-FX - Your Trusted Companion for Asthma and Allergic Rhinitis Management!<br />*Product Overview:*- Brand Name: Carelukast-FX Tablets- Composition: Montelukast (10mg) + Fexofenadine (120mg)<br />*Key Features:*1. *Dual Action Formula:* Carelukast-FX combines the anti-inflammatory action of Montelukast with the antihistaminic effect of Fexofenadine, providing comprehensive relief from symptoms associated with asthma and allergic rhinitis.2. *Leukotriene Receptor Antagonist:* Montelukast blocks the action of leukotrienes, substances in the body that cause inflammation, leading to improved asthma control and reduced frequency of asthma attacks.3. *Antihistaminic Effect:* Fexofenadine blocks the action of histamine, a chemical released during allergic reactions, relieving symptoms such as sneezing, itching, and nasal congestion associated with allergic rhinitis.4. *Symptom Relief:* With its synergistic action, Carelukast-FX offers rapid and lasting relief from symptoms of asthma and allergic rhinitis, allowing patients to breathe easy and enjoy a better quality of life.<br />*Indications:*Carelukast-FX is indicated for the:- Maintenance treatment of asthma in adults and pediatric patients- Relief of symptoms of allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea<br />*Dosage and Administration:*- Adults and Children ≥12 years: One tablet daily, preferably in the evening, with or without food.- Children 6-11 years: One tablet daily, under the guidance of a healthcare professional.<br />*Precautions and Warnings:*- Pregnancy and Lactation: Use with caution during pregnancy and breastfeeding, and only if the potential benefits outweigh the risks.- Hepatic Impairment: Adjust dosage in patients with moderate to severe hepatic impairment.- Renal Impairment: No dosage adjustment necessary in patients with renal impairment.<br />*Adverse Reactions:*- Common adverse effects include headache, dizziness, drowsiness, dry mouth, and gastrointestinal disturbances.- Rare but serious adverse reactions such as neuropsychiatric events, hypersensitivity reactions, and hepatotoxicity may occur.<br />
Central African Republic (République centrafricaine)+236
Chad (Tchad)+235
Chile+56
China (中国)+86
Christmas Island+61
Cocos (Keeling) Islands+61
Colombia+57
Comoros (جزر القمر)+269
Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
Congo (Republic) (Congo-Brazzaville)+242
Cook Islands+682
Costa Rica+506
Côte d’Ivoire+225
Croatia (Hrvatska)+385
Cuba+53
Curaçao+599
Cyprus (Κύπρος)+357
Czech Republic (Česká republika)+420
Denmark (Danmark)+45
Djibouti+253
Dominica+1
Dominican Republic (República Dominicana)+1
Ecuador+593
Egypt (مصر)+20
El Salvador+503
Equatorial Guinea (Guinea Ecuatorial)+240
Eritrea+291
Estonia (Eesti)+372
Eswatini+268
Ethiopia+251
Falkland Islands (Islas Malvinas)+500
Faroe Islands (Føroyar)+298
Fiji+679
Finland (Suomi)+358
France+33
French Guiana (Guyane française)+594
French Polynesia (Polynésie française)+689
Gabon+241
Gambia+220
Georgia (საქართველო)+995
Germany (Deutschland)+49
Ghana (Gaana)+233
Gibraltar+350
Greece (Ελλάδα)+30
Greenland (Kalaallit Nunaat)+299
Grenada+1
Guadeloupe+590
Guam+1
Guatemala+502
Guernsey+44
Guinea (Guinée)+224
Guinea-Bissau (Guiné Bissau)+245
Guyana+592
Haiti+509
Honduras+504
Hong Kong (香港)+852
Hungary (Magyarország)+36
Iceland (Ísland)+354
India (भारत)+91
Indonesia+62
Iran (ایران)+98
Iraq (العراق)+964
Ireland+353
Isle of Man+44
Israel (ישראל)+972
Italy (Italia)+39
Jamaica+1
Japan (日本)+81
Jersey+44
Jordan (الأردن)+962
Kazakhstan (Казахстан)+7
Kenya+254
Kiribati+686
Kosovo+383
Kuwait (الكويت)+965
Kyrgyzstan (Кыргызстан)+996
Laos (ລາວ)+856
Latvia (Latvija)+371
Lebanon (لبنان)+961
Lesotho+266
Liberia+231
Libya (ليبيا)+218
Liechtenstein+423
Lithuania (Lietuva)+370
Luxembourg+352
Macau (澳門)+853
North Macedonia (Македонија)+389
Madagascar (Madagasikara)+261
Malawi+265
Malaysia+60
Maldives+960
Mali+223
Malta+356
Marshall Islands+692
Martinique+596
Mauritania (موريتانيا)+222
Mauritius (Moris)+230
Mayotte+262
Mexico (México)+52
Micronesia+691
Moldova (Republica Moldova)+373
Monaco+377
Mongolia (Монгол)+976
Montenegro (Crna Gora)+382
Montserrat+1
Morocco (المغرب)+212
Mozambique (Moçambique)+258
Myanmar (Burma) (မြန်မာ)+95
Namibia (Namibië)+264
Nauru+674
Nepal (नेपाल)+977
Netherlands (Nederland)+31
New Caledonia (Nouvelle-Calédonie)+687
New Zealand+64
Nicaragua+505
Niger (Nijar)+227
Nigeria+234
Niue+683
Norfolk Island+672
North Korea (조선 민주주의 인민 공화국)+850
Northern Mariana Islands+1
Norway (Norge)+47
Oman (عُمان)+968
Pakistan (پاکستان)+92
Palau+680
Palestine (فلسطين)+970
Panama (Panamá)+507
Papua New Guinea+675
Paraguay+595
Peru (Perú)+51
Philippines+63
Poland (Polska)+48
Portugal+351
Puerto Rico+1
Qatar (قطر)+974
Réunion (La Réunion)+262
Romania (România)+40
Russia (Россия)+7
Rwanda+250
Saint Barthélemy+590
Saint Helena+290
Saint Kitts and Nevis+1
Saint Lucia+1
Saint Martin (Saint-Martin (partie française))+590
Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
Saint Vincent and the Grenadines+1
Samoa+685
San Marino+378
São Tomé and Príncipe (São Tomé e Príncipe)+239
Saudi Arabia (المملكة العربية السعودية)+966
Senegal (Sénégal)+221
Serbia (Србија)+381
Seychelles+248
Sierra Leone+232
Singapore+65
Sint Maarten+1
Slovakia (Slovensko)+421
Slovenia (Slovenija)+386
Solomon Islands+677
Somalia (Soomaaliya)+252
South Africa+27
South Korea (대한민국)+82
South Sudan (جنوب السودان)+211
Spain (España)+34
Sri Lanka (ශ්රී ලංකාව)+94
Sudan (السودان)+249
Suriname+597
Svalbard and Jan Mayen+47
Sweden (Sverige)+46
Switzerland (Schweiz)+41
Syria (سوريا)+963
Taiwan (台灣)+886
Tajikistan+992
Tanzania+255
Thailand (ไทย)+66
Timor-Leste+670
Togo+228
Tokelau+690
Tonga+676
Trinidad and Tobago+1
Tunisia (تونس)+216
Turkey (Türkiye)+90
Turkmenistan+993
Turks and Caicos Islands+1
Tuvalu+688
U.S. Virgin Islands+1
Uganda+256
Ukraine (Україна)+380
United Arab Emirates (الإمارات العربية المتحدة)+971
United Kingdom+44
United States+1
Uruguay+598
Uzbekistan (Oʻzbekiston)+998
Vanuatu+678
Vatican City (Città del Vaticano)+39
Venezuela+58
Vietnam (Việt Nam)+84
Wallis and Futuna (Wallis-et-Futuna)+681
Western Sahara (الصحراء الغربية)+212
Yemen (اليمن)+967
Zambia+260
Zimbabwe+263
Åland Islands+358
Description:
Packaging Size
100 Tablets
Packaging Type
10x10 Alu-Alu
Brand
CARELUKAST-FX
Also gives
PCD Pharma, Third Party Manufacturing, Export
Country of Origin
Made in India
Welcome to Carelukast-FX - Your Trusted Companion for Asthma and Allergic Rhinitis Management!<br />*Product Overview:*- Brand Name: Carelukast-FX Tablets- Composition: Montelukast (10mg) + Fexofenadine (120mg)<br />*Key Features:*1. *Dual Action Formula:* Carelukast-FX combines the anti-inflammatory action of Montelukast with the antihistaminic effect of Fexofenadine, providing comprehensive relief from symptoms associated with asthma and allergic rhinitis.2. *Leukotriene Receptor Antagonist:* Montelukast blocks the action of leukotrienes, substances in the body that cause inflammation, leading to improved asthma control and reduced frequency of asthma attacks.3. *Antihistaminic Effect:* Fexofenadine blocks the action of histamine, a chemical released during allergic reactions, relieving symptoms such as sneezing, itching, and nasal congestion associated with allergic rhinitis.4. *Symptom Relief:* With its synergistic action, Carelukast-FX offers rapid and lasting relief from symptoms of asthma and allergic rhinitis, allowing patients to breathe easy and enjoy a better quality of life.<br />*Indications:*Carelukast-FX is indicated for the:- Maintenance treatment of asthma in adults and pediatric patients- Relief of symptoms of allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea<br />*Dosage and Administration:*- Adults and Children ≥12 years: One tablet daily, preferably in the evening, with or without food.- Children 6-11 years: One tablet daily, under the guidance of a healthcare professional.<br />*Precautions and Warnings:*- Pregnancy and Lactation: Use with caution during pregnancy and breastfeeding, and only if the potential benefits outweigh the risks.- Hepatic Impairment: Adjust dosage in patients with moderate to severe hepatic impairment.- Renal Impairment: No dosage adjustment necessary in patients with renal impairment.<br />*Adverse Reactions:*- Common adverse effects include headache, dizziness, drowsiness, dry mouth, and gastrointestinal disturbances.- Rare but serious adverse reactions such as neuropsychiatric events, hypersensitivity reactions, and hepatotoxicity may occur.<br />